Alps Group, Inc. operates as a biotechnology company that integrates research and development, medical services, and wellness solutions. The firm has cultivated a diverse pipeline covering various biotechnology research areas. This includes initiatives focused on MyImmune (NK cells), CAR-T cells, COVID-19 mRNA vaccine, diabetes therapeutics, and advancements in stem cell technologies such as induced Pluripotent Stem Cells (iPSCs) and messenger ribonucleic acid (mRNA) platform technology. The firm provides aesthetic treatments, cosmetic procedures, general healthcare and wellness services. The Company’s aesthetic services and cosmetic surgery services include non-surgical aesthetic services and surgical aesthetic services. The company operates a molecular laboratory and a cGMP cell and gene therapy research and cultivation laboratory.
根据最新的财务报表(Form-10K),Alps Group Inc 的总资产为 $0,净損失为 $0
GLLIR 的关键财务比率是什么?
Alps Group Inc 的流动比率是 0,净利 margin 为 0,每股销售为 $0。
Alps Group Inc 的收入按细分市场或地理位置如何划分?
Alps Group Inc 最大收入來源為 Diagnostic Instruments, Reagents and Ancillary Products,在最近的收益報告中收入為 50,194,000。就地區而言,United States 是 Alps Group Inc 的主要市場,收入為 26,166,000。